Currently, a combination of lapatinib and capecitabine has been approved for use in patients with advanced HER2-positive breast cancer after treatment with chemotherapy using dual anti-HER2 therapy; trastuzumab and pertuzumab [8]. The gene discussed is ERBB2; the disease is breast carcinoma.